PatientView has published their annual survey ‘The Corporate Reputation of Pharma’, ranking Lundbeck as number 8 in corporate reputation based on feedback from 1,075 patient groups. In 2015, Lundbeck was ranked as 3rd.
Read the release from PatientView.
Working with patients makes a difference
Lundbeck is in the top tier for four of the seven indicators that drive pharmaceutical companies’ reputation among patient groups: patient centricity, patient-group relationships, patient information and usefulness of products. For the remaining three indicators patient safety, transparency and integrity Lundbeck is ranked in the middle tier.
In the survey, patient groups give input on how pharma can improve their reputation. Most important is good patient-group relationships, patient centricity, fair pricing, high-quality products and patient safety.
“We can all be proud of this recognition by patient groups. Being ranked as a top tier company among global pharmaceutical companies underscores our passion and efforts in helping patients and communities affected by psychiatric and neurological disorders,” says CEO Kåre Schultz, and continues:
“The ranking is based on patient groups familiar with Lundbeck. The survey also shows that Lundbeck’s reputation is significantly better among patient groups having worked with us. This is positive and confirms the importance of our engagement and activities with patient advocacy groups locally and globally. Through these activities we can improve lives of patients and thereby support our strive for global leadership in psychiatry and neurology.”